Home / MarketersMEDIA

Nurosym Vs Nuropod: AVNT Vagus Nerve Device Differences Explained In Guide

A new guide explains that Nurosym and Nuropod use the same AVNT™ vagus nerve stimulation technology and are designed for different regional markets, with practical differences in pricing, shipping, and customer support.

Sacramento, United States, November 19, 2026 -- Parasym, the London-based neurotechnology company behind Nurosym and Nuropod, has published a guide that answers a question common among people researching vagus nerve stimulation devices: whether the two products are the same, and which one to buy. According to the guide, both devices deliver Parasym’s Auricular Vagal Neuromodulation Therapy, or AVNT, and the choice depends on where the buyer lives.

Nuropod is offered in the United States, Canada, Australia, and New Zealand, while Nurosym serves the UK, Europe, and select other markets, according to the guide. Parasym introduced Nuropod in the United States on September 5, 2025, because Nurosym was not available there. The guide says the distinction centers on regional pricing, shipping, customer support, warranty handling, and the regulatory framework in each market, rather than on a different stimulation method.

Research interest in transcutaneous auricular vagus nerve stimulation, or taVNS, continues to grow. A 2026 review published in Frontiers in Neurology, which included 72 articles, describes taVNS as a noninvasive neuromodulation technique that has attracted significant attention, while also examining its safety profile and the challenges that limit its translation into clinical practice.

Both devices use an earpiece positioned at the tragus, where the vagus nerve reaches the skin of the ear, to deliver Parasym’s AVNT waveform. Parasym reports that the technology has been evaluated in more than 60 completed studies with more than 150 research partners. The company notes that the research referenced was conducted under research conditions and relates to specific study populations.

According to the guide, buying from the regional brand provides customer support in the buyer’s time zone and language, pricing in local currency, shipping from regional distribution centers, and warranty and returns handled through local channels. In the United States, Nuropod is priced and supported locally, while Nurosym fills the equivalent role across European markets. Parasym describes Nurosym as a CE-marked medical device in Europe and Nuropod as its wellness device for the U.S. market.

Dr. Elisabetta Burchi, Translational Research Lead at Parasym, said the company has been able to “translate years of research and development into a user-centric product.”

The guide’s central message is that location, not a difference in core AVNT technology, should determine which product a buyer purchases.

About Parasym

Founded in 2015 and based in London, Parasym Scientific (Parasym) is a neurotechnology company developing noninvasive auricular vagus nerve stimulation technology based on its AVNT waveform. Its consumer devices are marketed as Nurosym in the UK, Europe, and other international markets, and as Nuropod in the United States and selected other regions.

More information about Nuropod and Parasym’s AVNT technology can be found at https://nuropod.com/blogs/articles/nurosym-vs-nuropod-what-are-the-differences

Disclaimer: Research referenced in this article was conducted using Parasym's neuromodulation technology under research conditions. Findings relate to specific study populations and should not be interpreted as guaranteed individual outcomes. Nuropod is classified by the FDA as a non-significant risk device and is not intended to diagnose, treat, cure, or prevent any disease.

Contact Info:
Name: PR Team
Email: Send Email
Organization: Nuropod by Parasym
Address: 2108 N Street, Sacramento, California 95816, United States
Website: https://nuropod.com/

Source: PressCable

Release ID: 89210199

If you detect any issues, problems, or errors in this press release content, kindly contact error@releasecontact.com to notify us (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). We will respond and rectify the situation in the next 8 hours.

Source: MarketersMedia

Leave a comment

Comments are closed on this post.

Related